365410-36-2

Upstream product

• 365410-29-3 (1α,2α,3β,4β)-1,3-Bis{1,9-dihydro-1,9-bis[(tert-butyldimethylsilyloxy)methyl]-2-oxo-2H-purin-6-yl}-2,4-diphenylcyclobutane 
• 365410-31-7 1,9-Dihydro-1,9-bis[(tert-butyldimethylsilyloxy)methyl]-2H-purin-2-one 
• 119451-80-8 (chloromethoxy)(1,1-dimethylethyl)dimethylsilane 
• 588-72-7 [(E)-2-bromoethenyl]benzene 
• 365410-35-1 (E)-1,9-Dihydro-1,9-bis[(tert-butyldimethylsilyloxy)methyl]-6-[2-(phenyl)ethenyl]-2H-purin-2-one 

Downstream Products

• 365410-50-0 (Z)-1,9-Dihydro-6-[2-(phenyl)ethenyl]-2H-purin-2-one 

Relevant academic research and scientific papers

Synthesis of 6-substituted purin-2-ones with potential cytokinin activity

6-Substituted purin-2-ones have been prepared by completely regioselective addition of Grignard reagents to an N-protected purin-2-one followed by rearomatisation and deprotection. The target compounds may be regarded as analogues of the potent cytokinins trans-zeatin and benzylaminopurine (BAP), and most of the BAP analogues did induce increased weight growth in radish cotyledons. N-Protected (E)-6-styrylpurin-2-one underwent head to tail [2+2] dimerisation to the 1α,2α,3β,4β-substituted cyclobutane 15, when exposed to ordinary daylight. When irradiated with UV-light, the trans-compound isomerised to the corresponding cis-isomer. The structure of compound 15 was determined by single crystal X-ray di3raction methods at 150 K.